Medical Scientist Training Program
http://www.mstp.uab.edu
Back to Main
Faculty Detail
Name
MARY-ANN BJORNSTI
Professor and Chair, Department of Pharmacology and Toxicology
Newman H. Waters Chair of Clinical Pharmacology
Associate Director for Translational Research, UAB Comprehensive Cancer Center
Campus Address
VH 140
Phone
(205) 934-4579
E-mail
bjornsti@uab.edu
Other websites
Education
Graduate
University of Minnesota
1983
PhD
Faculty Appointment(s)
Appointment Type
Department
Division
Rank
Primary
School of Medicine Dean's Office
School of Medicine Dean's Office
Professor Emeritus
Graduate Biomedical Sciences Affiliations
Biochemistry and Structural Biology
Cancer Biology
Medical Scientist Training Program
Biographical Sketch
NY State University, College at Cortland BS in Biology, 1978 University of Minnesota, Minneapolis, MN PhD in Genetics & Cell Biology, 1983 Biozentrum U. of Basel, Basel, Switzerland Fogarty Post-doctoral Fellow, 1983-85 Harvard University, Cambridge MA Post-doctoral Fellow, 1985-89 Thomas Jefferson University, Philadelphia PA Asst/Assoc Professor, 1989-99 St Jude Children’s Research Hospital, Memphis TN Assoc/Full Member, 1999-2009 St Jude Children’s Research Hospital, Memphis TN Member, Developmental Therapeutics of Solid Malignancies Program 1999-2009 University of Alabama at Birmingham, Pharmacology & Toxicology Professor and Chair, 2009- UAB Comprehensive Cancer Center Assoc Director for Translational Research, 2009- UAB Comprehensive Cancer Center Co-Leader, Cancer Cell Biology Program, 2009-
Society Memberships
Organization Name
Position Held
Org Link
Association of Medical School Pharmacology Chairs
Secretary, President-elect
Research/Clinical Interest
Title
Description
Mary-Ann Bjornsti, PhD has long-standing research interests in the mechanisms of anti-cancer drug action and in pathways regulating tumor growth and chemotherapeutic response. As a post-doc at Harvard University, she pioneered the use of the genetically tractable yeast model system to investigate the mechanism of action of DNA topoisomerase I and chemotherapeutics that target this enzyme. At Thomas Jefferson University, her lab expanded these studies to include genetic and biochemical studies of cellular pathways dictating tumor cell response to these drugs. At St Jude Children’s Research Hospital and at UAB, her lab has focused on translating basic mechanisms of chemotherapeutic drug action and cellular pathways that regulated responses to these agents to human cell lines and mouse models. Her lab has partnered with the UAB Alabama drug discovery alliance and Southern Research to establish genome-wide siRNA screening capabilities that complement state-of-the-art chemistry and small molecule screening platforms at Southern Research. She had developed extensive collaborative efforts with Members of the UAB Comprehensive Cancer Center and the Breast Cancer SPORE to investigate pathways that regulate cellular responses to topoisomerase I-induced DNA damage, the functional consequences of protein SUMOylation on cellular responses to genotoxic stresses, and the role of TOR signaling in the DNA damage response.
Keywords
DNA topoisomerase I, yeast genetics, cancer chemotherapeutics, TOR signaling, SUMOylation, DNA damage response, drug resistance, siRNA screening, breast cancer
